Clinical trial pay now tax-free, protecting low-income participants
S. 5127 — Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026 · Filed by Jim Banks (R-IN) · 2 cosponsors · Introduced Jul 23, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill exempts compensation paid to clinical trial participants from federal income tax and excludes it from counting as income when determining eligibility for federal assistance programs (like Medicaid, SNAP, housing assistance). Participants can receive payment for their time and reimbursement for trial-related expenses without triggering tax liability or losing benefits.
Why we flagged it
The bill's operative mechanism is a tax and benefit-eligibility exemption designed to remove financial disincentives for clinical trial participation. It is not a general tax cut or subsidy to industry, but rather a targeted removal of a penalty on individual participants.
What the text implies
- Pharmaceutical and biotech companies may benefit indirectly by reducing recruitment friction for trials, potentially lowering trial costs and accelerating enrollment — a private benefit not explicitly stated in the bill's civic framing.
- The exemption applies retroactively to payments made after December 31, 2025, creating a tax-filing adjustment window that may require IRS guidance and administrative burden.
- By excluding trial income from means-tested benefit calculations, the bill may reduce federal and state spending on safety-net programs for trial participants, shifting the cost burden away from government.
- The bill does not cap the amount of trial compensation that can be excluded, potentially allowing high-value trial payments to escape taxation entirely, creating an unequal tax treatment compared to other earned income.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill removes a financial penalty that currently discourages low-income and vulnerable people from participating in medical research. By exempting trial payments from income taxation and means-tested benefit calculations, it lowers barriers to participation in clinical trials that may advance medical knowledge and treatment options, while protecting participants from losing essential safety-net benefits.
Who stands to gain
- pharmaceutical companies
- biotech firms
- contract research organizations (CROs)
- clinical trial sponsors
Named in the bill
Internal Revenue Code, Public Health Service Act, Section 139M, Section 2709, FDA, Medicaid, SNAP, BMY (Bristol Myers Squibb), PFE (Pfizer), JNJ (Johnson & Johnson), GH (Guardant Health), DVA (DaVita)
Where it stands
2 cosponsors: 1 Democrats, 1 Republicans.
- Jul 23, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jul 23, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,480 characters) on Aug 5, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Clinical trial pay now tax-free, protecting low-income participants” QuorumCivic. https://share.quorumcivic.app/bill/119/s5127 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.